Critique on the Generalizability of a Proposed Clinical Management Algorithm for Atypia of Undetermined Significance ( AUS ) in the Absence of Molecular Testing in Thyroidology

This Letter to the Editor critically appraises a recent proposal for managing Atypia of Undetermined Significance (AUS) in thyroid fine‐needle aspiration cytology without molecular testing. The authors argue that the algorithm's success is intrinsically linked to the specialised, high‐volume center where the data originated, limiting its broad applicability due to variations in AUS rates, risk of malignancy, and regional clinical practices.